AbbVie
ABBV
#27
Rank
NZ$669.08 B
Marketcap
NZ$378.28
Share price
2.05%
Change (1 day)
4.22%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) - Total debt

Total debt on the balance sheet as of December 2025 : NZ$117.39 Billion

According to AbbVie's latest financial reports the company's total debt is NZ$117.39 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

AbbVie - Total debt on balance sheet (from 2011 to 2025)

Total debt by year

Year Total debt Change
2025-12-31NZ$116.54 B-2.11%
2024-12-31NZ$119.05 B26.78%
2023-12-31NZ$93.90 B-5.77%
2022-12-31NZ$99.65 B-11.23%
2021-12-31NZ$112.26 B-5.87%
2020-12-31NZ$119.26 B20.37%
2019-12-31NZ$99.07 B64.87%
2018-12-31NZ$60.09 B14.21%
2017-12-31NZ$52.61 B-1.07%
2016-12-31NZ$53.18 B14.94%
2015-12-31NZ$46.27 B142.08%
2014-12-31NZ$19.11 B6.69%
2013-12-31NZ$17.91 B-5.95%
2012-12-31NZ$19.05 B30875.84%
2011-12-31NZ$61.5 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
NZ$111.24 B-5.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$73.92 B-37.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$94.97 B-19.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$11.43 B-90.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$43.37 B-63.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$81.98 B-30.16%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$50.69 B-56.81%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$41.50 B-64.64%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$0.72 B-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA